New immunotherapy combo aims to fight unresectable lung cancer
NCT ID NCT07619911
First seen Jun 03, 2026 · Last updated Jun 20, 2026 · Updated 4 times
Summary
This phase II trial tests an immunotherapy drug called SHR-1701 combined with chemotherapy and radiation for people with stage III non-small cell lung cancer that cannot be removed by surgery. The study will compare giving SHR-1701 before or after standard chemoradiation. The main goal is to see if it delays cancer growth. About 84 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMORADIOTHERAPY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR-1701 (an immunotherapy drug) combined with chemotherapy and radiation
What this could lead to
If it works, this could offer a new treatment option for people with stage III lung cancer that can't be removed by surgery, potentially helping them live longer without the cancer growing.
What could go wrong
This is an early phase II trial with only 84 people, so results are not definitive. The drug may not improve outcomes and could cause side effects like immune-related inflammation.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.